Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A-Mutated Advanced Urothelial Carcinoma

Sumati Gupta, Daniel J. Albertson, Timothy J. Parnell, Andrew Butterfield, Alexis Weston, Lisa M. Pappas, Brian Dalley, John M. O’Shea, William T. Lowrance, Bradley R. Cairns, Joshua D. Schiffman, Sunil Sharma

Mol Cancer Ther (2019) 18 (1): 185–195.

https://doi.org/10.1158/1535-7163.MCT-17-0957

Published: 02 January 2019

View article titled, Histone Deacetylase Inhibition Has Targeted Clinical Benefit in <em>ARID1A</em>-Mutated Advanced Urothelial Carcinoma

Includes: Supplementary data

Journal Articles

Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response

Kathleen I. Pishas, Christina D. Drenberg, Cenny Taslim, Emily R. Theisen, Kirsten M. Johnson, Ranajeet S. Saund, Ioana L. Pop, Brian D. Crompton, Elizabeth R. Lawlor, Franck Tirode, Jaume Mora, Olivier Delattre, Mary C. Beckerle, David F. Callen, Sunil Sharma, Stephen L. Lessnick

Mol Cancer Ther (2018) 17 (9): 1902–1916.

https://doi.org/10.1158/1535-7163.MCT-18-0373

Published: 04 September 2018

View article titled, Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response

Includes: Supplementary data

Journal Articles

Abstract B176: Results of a phase I study of PLX8394, a next-generation BRAF inhibitor, in refractory solid tumors

Filip Janku, Ulka Vaishampayan, Vivek Khemka, Minny Bhatty, Chao Zhang, Henry H. Hsu, Paul S. Lin, Sandra Tong, Sunil Sharma

Mol Cancer Ther (2018) 17 (1_Supplement): B176.

https://doi.org/10.1158/1535-7163.TARG-17-B176

Published: 01 January 2018

View article titled, Abstract B176: Results of a phase I study of PLX8394, a next-generation BRAF inhibitor, in refractory solid tumors

Journal Articles

Abstract B147: A phase 1 drug-drug interaction study between ixazomib, an oral proteasome inhibitor, and rifampin in patients (pts) with advanced solid tumors

Neeraj Gupta, Michael J. Hanley, Karthik Venkatakrishnan, Alberto Bessudo, Sunil Sharma, Bert O'Neil, Bingxia Wang, Ai-Min Hui, John Nemunaitis

Mol Cancer Ther (2015) 14 (12_Supplement_2): B147.

https://doi.org/10.1158/1535-7163.TARG-15-B147

Published: 01 December 2015

View article titled, Abstract B147: A phase 1 drug-drug interaction study between ixazomib, an oral proteasome inhibitor, and rifampin in patients (pts) with advanced solid tumors

Journal Articles

Abstract C92: HCI-2577 inhibits LSD1 and modulates histone marks in Ewing's sarcoma models

Jared J. Bearss, Adrianne Neiss, Xiao-Hui Liu, Hariprasad Vankayalapati, Sunil Sharma

Mol Cancer Ther (2015) 14 (12_Supplement_2): C92.

https://doi.org/10.1158/1535-7163.TARG-15-C92

Published: 01 December 2015

View article titled, Abstract C92: HCI-2577 inhibits LSD1 and modulates histone marks in Ewing's sarcoma models

Journal Articles

Abstract C91: Reversible lysine specific demethylase-1 inhibition is synergistic with docetaxel in castrate refractory prostate cancer

Sumati Gupta, Alexis Weston, Jared Bearss, Sunil Sharma

Mol Cancer Ther (2015) 14 (12_Supplement_2): C91.

https://doi.org/10.1158/1535-7163.TARG-15-C91

Published: 01 December 2015

View article titled, Abstract C91: Reversible lysine specific demethylase-1 inhibition is synergistic with docetaxel in castrate refractory prostate cancer

Journal Articles

BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD

Warren Fiskus, Sunil Sharma, Jun Qi, Bhavin Shah, Santhana G.T. Devaraj, Christopher Leveque, Bryce P. Portier, Swaminathan Iyer, James E. Bradner, Kapil N. Bhalla

Mol Cancer Ther (2014) 13 (10): 2315–2327.

https://doi.org/10.1158/1535-7163.MCT-14-0258

Published: 02 October 2014

View article titled, BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD

Includes: Supplementary data

Journal Articles

Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells

Warren Fiskus, Sunil Sharma, Jun Qi, John A. Valenta, Leasha J. Schaub, Bhavin Shah, Karissa Peth, Bryce P. Portier, Melissa Rodriguez, Santhana G.T. Devaraj, Ming Zhan, Jianting Sheng, Swaminathan P. Iyer, James E. Bradner, Kapil N. Bhalla

Mol Cancer Ther (2014) 13 (5): 1142–1154.

https://doi.org/10.1158/1535-7163.MCT-13-0770

Published: 05 May 2014

View article titled, Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells

Includes: Supplementary data

Journal Articles

Abstract A124: Co-treatment with BRD4 antagonist and histone deacetylase inhibitor is synergistically lethal against Mantle Cell Lymphoma (MCL) cells.

Bhavin Shah, Laxmi Jakkula, Warren Fiskus, Sunil Sharma, Jun Qi, John A. Valenta, Leasha J. Schaub, Melissa Rodriguez, Santhana G.T. Devaraj, James E. Bradner, Kapil N. Bhalla

Mol Cancer Ther (2013) 12 (11_Supplement): A124.

https://doi.org/10.1158/1535-7163.TARG-13-A124

Published: 01 November 2013

View article titled, Abstract A124: Co-treatment with BRD4 antagonist and histone deacetylase inhibitor is synergistically lethal against Mantle Cell Lymphoma (MCL) cells.

Journal Articles

Abstract C144: Treatment with β-catenin antagonist BC2059 exhibits single agent efficacy and exerts superior activity with tyrosine kinase inhibitor (TKI) or histone deacetylase (HDAC) inhibitor against human AML, CML, and myeloproliferative neoplasm (MPN) progenitor cells.

Warren Fiskus, Jacqueline Smith, Uma Mudunuru, Stacey Hembruff, Ruben Reyes, Sunil Abhyankar, Joseph McGuirk, Omar Aljitawi, Siddhartha Ganguly, Stephen Horrigan, Sunil Sharma, Kapil N. Bhalla

Mol Cancer Ther (2011) 10 (11_Supplement): C144.

https://doi.org/10.1158/1535-7163.TARG-11-C144

Published: 12 November 2011

View article titled, Abstract C144: Treatment with β-catenin antagonist BC2059 exhibits single agent efficacy and exerts superior activity with tyrosine kinase inhibitor (TKI) or histone deacetylase (HDAC) inhibitor against human AML, CML, and myeloproliferative neoplasm (MPN) progenitor cells.

Journal Articles

Abstract B84: HCI-2528 is a potent inhibitor of LSD1 with improved druglike characteristics.

Bret J. Stephens, Venkataswamy Sorna, Emily Theisen, Hariprasad Vankayalapati, Steven Warner, David Bearss, Sunil Sharma

Mol Cancer Ther (2011) 10 (11_Supplement): B84.

https://doi.org/10.1158/1535-7163.TARG-11-B84

Published: 12 November 2011

View article titled, Abstract B84: HCI-2528 is a potent inhibitor of LSD1 with improved druglike characteristics.

Journal Articles

Targeting Axl and Mer Kinases in Cancer

Anupam Verma, Steven L. Warner, Hariprasad Vankayalapati, David J. Bearss, Sunil Sharma

Mol Cancer Ther (2011) 10 (10): 1763–1773.

https://doi.org/10.1158/1535-7163.MCT-11-0116

Published: 09 October 2011

View article titled, Targeting Axl and Mer Kinases in Cancer

Journal Articles

Abstract C131: CBP501 (CBP), a novel cell cycle dysregulator, in combination with cisplatin (CDDP) and pemetrexed (PM) ‐ pharmacokinetics (PK) in two phase I/II studies

Sunil Sharma, Raoul Tibes, Ernesto Wasserman, Cristian Fernandez, William Sutherland, Scott Slough, Takumi Kawabe, Hitoshi Sato, Yoshimasa Ginbara, Daniel Von Hoff, Geoffrey I. Shapiro

Mol Cancer Ther (2009) 8 (12_Supplement): C131.

https://doi.org/10.1158/1535-7163.TARG-09-C131

Published: 10 December 2009

View article titled, Abstract C131: CBP501 (CBP), a novel cell cycle dysregulator, in combination with cisplatin (CDDP) and pemetrexed (PM) ‐ pharmacokinetics (PK) in two phase I/II studies

Journal Articles

Abstract C36: MBP‐426, a novel liposome‐encapsulated oxaliplatin, in combination with 5‐FU/leucovorin (LV): Phase I results of a Phase I/II study in gastro‐esophageal adenocarcinoma, with pharmacokinetics

Neil N. Senzer, Kazuhiko Matsuno, Nobuyuki Yamagata, Tadashi Fujisawa, Ernesto Wasserman, William Sutherland, Sunil Sharma, Alexandria Phan

Mol Cancer Ther (2009) 8 (12_Supplement): C36.

https://doi.org/10.1158/1535-7163.TARG-09-C36

Published: 10 December 2009

View article titled, Abstract C36: MBP‐426, a novel liposome‐encapsulated oxaliplatin, in combination with 5‐FU/leucovorin (LV): Phase I results of a Phase I/II study in gastro‐esophageal adenocarcinoma, with pharmacokinetics

Journal Articles

Abstract B47: CBP501, a novel cell cycle dysregulator, in combination with cisplatin (CDDP) and pemetrexed (PM) ‐ results of two phase I/II studies

Sunil Sharma, Raoul Tibes, Bruno Bastos, Mitesh Borad, Bryan Wong, Ernesto Wasserman, Cristian Fernandez, Takumi Kawabe, Daniel Von Hoff, Geoffrey I. Shapiro

Mol Cancer Ther (2009) 8 (12_Supplement): B47.

https://doi.org/10.1158/1535-7163.TARG-09-B47

Published: 10 December 2009

View article titled, Abstract B47: CBP501, a novel cell cycle dysregulator, in combination with cisplatin (CDDP) and pemetrexed (PM) ‐ results of two phase I/II studies

Journal Articles

Abstract B11: Preclinical and preliminary phase 1 trial results of JI‐101: A novel, oral tyrosine kinase inhibitor that selectively targets VEGFR2, EphB4, and PDGFR

Mark Velleca, David Brittelli, Lisa Elkin, Udo Klein, Scott Mitchell, Dapeng Qian, Xiaobing Qian, Sreesha Srinivasa, Thomas Stephan, Raman Govindarajan, Warren Stern, Michael Gordon, Sunil Sharma, Linda Miller

Mol Cancer Ther (2009) 8 (12_Supplement): B11.

https://doi.org/10.1158/1535-7163.TARG-09-B11

Published: 10 December 2009

View article titled, Abstract B11: Preclinical and preliminary phase 1 trial results of JI‐101: A novel, oral tyrosine kinase inhibitor that selectively targets VEGFR2, EphB4, and PDGFR

Journal Articles

Mesothelioma and lung cancer cell lines differentially express the protein kinase G splice variants PKG-Iα and PKG-Iβ: Involvement in regulating apoptosis

Ronald Fiscus, Mary Johlfs, Madhavi Bathina, Cheuk-Ying Wong, Sunil Sharma, Nicholas Vogelzang

Mol Cancer Ther (2007) 6 (11_Supplement): C182.

Published: 01 November 2007

View article titled, Mesothelioma and lung cancer cell lines differentially express the protein kinase G splice variants PKG-Iα and PKG-Iβ: Involvement in regulating apoptosis

Journal Articles

Preclinical and Clinical Pharmacodynamic Assessment of L-778,123, a Dual Inhibitor of Farnesyl:Protein Transferase and Geranylgeranyl:Protein Transferase Type-I

Mol Cancer Ther (2002) 1 (9): 747–758.

Published: 01 July 2002

View article titled, Preclinical and Clinical Pharmacodynamic Assessment of L-778,123, a Dual Inhibitor of Farnesyl:Protein Transferase and Geranylgeranyl:Protein Transferase Type-I

NARROW

Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A-Mutated Advanced Urothelial Carcinoma

Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response

Abstract B176: Results of a phase I study of PLX8394, a next-generation BRAF inhibitor, in refractory solid tumors

Abstract B147: A phase 1 drug-drug interaction study between ixazomib, an oral proteasome inhibitor, and rifampin in patients (pts) with advanced solid tumors

Abstract C92: HCI-2577 inhibits LSD1 and modulates histone marks in Ewing's sarcoma models

Abstract C91: Reversible lysine specific demethylase-1 inhibition is synergistic with docetaxel in castrate refractory prostate cancer

BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD

Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells

Abstract A124: Co-treatment with BRD4 antagonist and histone deacetylase inhibitor is synergistically lethal against Mantle Cell Lymphoma (MCL) cells.

Abstract C144: Treatment with β-catenin antagonist BC2059 exhibits single agent efficacy and exerts superior activity with tyrosine kinase inhibitor (TKI) or histone deacetylase (HDAC) inhibitor against human AML, CML, and myeloproliferative neoplasm (MPN) progenitor cells.

Abstract B84: HCI-2528 is a potent inhibitor of LSD1 with improved druglike characteristics.

Targeting Axl and Mer Kinases in Cancer

Abstract C131: CBP501 (CBP), a novel cell cycle dysregulator, in combination with cisplatin (CDDP) and pemetrexed (PM) ‐ pharmacokinetics (PK) in two phase I/II studies

Abstract C36: MBP‐426, a novel liposome‐encapsulated oxaliplatin, in combination with 5‐FU/leucovorin (LV): Phase I results of a Phase I/II study in gastro‐esophageal adenocarcinoma, with pharmacokinetics

Abstract B47: CBP501, a novel cell cycle dysregulator, in combination with cisplatin (CDDP) and pemetrexed (PM) ‐ results of two phase I/II studies

Abstract B11: Preclinical and preliminary phase 1 trial results of JI‐101: A novel, oral tyrosine kinase inhibitor that selectively targets VEGFR2, EphB4, and PDGFR

Mesothelioma and lung cancer cell lines differentially express the protein kinase G splice variants PKG-Iα and PKG-Iβ: Involvement in regulating apoptosis

Preclinical and Clinical Pharmacodynamic Assessment of L-778,123, a Dual Inhibitor of Farnesyl:Protein Transferase and Geranylgeranyl:Protein Transferase Type-I

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only